Research

Austin Kirschner and colleagues demonstrate how a hormone therapy for prostate cancer improves radiation’s tumor-killing power.

Understanding details of how arrestins deactivate signaling by G-protein coupled receptors is key to the design of new therapeutics aimed at these cellular "inboxes" that are targeted by up to half of all pharmaceuticals.

Jonathan Schoenecker and colleagues have discovered a new mechanism for the formation of bone in soft tissues — a complication of severe injuries that causes pain and limits mobility.

A report by researchers at Vanderbilt University Medical Center has shattered conventional wisdom about how cells, including cancer cells, shed DNA into the bloodstream: they don’t do it by packaging the genetic material in tiny vesicles called exosomes.

Vanderbilt researchers led by Eric Skaar are probing the mechanisms bacteria use when faced with nutrient starvation — a host defense strategy called “nutritional immunity.”

When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.

Stephen Fesik and colleagues are advancing cancer drug discovery with the characterization of small molecules that modulate RAS, an important target for anti-cancer therapies.